Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. However, three Fool.com ...

However, Eli Lilly is gaining momentum, and expects significant catalysts that could send its stock price soaring in 2025.

And speaking of dividends, Novo Nordisk pays one, and it has increased its annual dividend per share by almost 284% in the ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the ...